Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Forecast
Analysts expect Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) to earn $1.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.21B. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $1.23.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.57, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 42.9% |
| Buy | 4 | 57.1% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 15.0% and revenue estimates rise 9.3%.
- Fiscal year ending Dec 31, 2026
- $1.07
- EPS consensus, revenue $3.21B
- Fiscal year ending Dec 31, 2027
- $1.23
- EPS consensus, revenue $3.51B
- Next report
- Feb 25, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.07 | $1.05 to $1.13 | 6 | $3.21B | $3.15B to $3.24B | 6 |
| Dec 31, 2027 | $1.23 | $1.13 to $1.34 | 7 | $3.51B | $3.38B to $3.67B | 6 |
Quarterly Estimates
The EPS consensus rises from $0.24 for the quarter ending Dec 31, 2026 to $0.26 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.24 | $0.22 to $0.26 | 9 | $860.29M | $810.32M to $899.85M | 8 |
| Mar 31, 2027 | $0.26 | $0.24 to $0.28 | 5 | $799.45M | $769.30M to $836.10M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.0% from $1.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.07 | $1.03 | $1.02 | $1.00 | $1.00 | +7.5% |
| Fiscal year ending Dec 31, 2027 | $1.23 | $1.21 | $1.19 | $1.16 | $1.18 | +4.2% |
| Quarter ending Mar 31, 2027 | $0.26 | $0.25 | $0.25 | $0.26 | $0.26 | +1.2% |
Frequently Asked Questions About AMRX
What is the AMRX stock forecast?
Consensus analyst estimates put Amneal Pharmaceuticals, Inc. Class A Common Stock's EPS at $1.07 for the fiscal year ending Dec 31, 2026, on revenue of $3.21B. The consensus rating from 7 analysts is Buy.
How do analysts rate AMRX stock?
Of 7 analysts covering Amneal Pharmaceuticals, Inc. Class A Common Stock, 3 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AMRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.07, with estimates from $1.05 to $1.13 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.23, with estimates from $1.13 to $1.34 from 7 analysts.
What revenue do analysts expect from Amneal Pharmaceuticals, Inc. Class A Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.21B, with estimates from $3.15B to $3.24B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.51B, with estimates from $3.38B to $3.67B.
How many analysts cover AMRX?
7 analysts rate Amneal Pharmaceuticals, Inc. Class A Common Stock stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AMRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors